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Background: Managing loss of response (LOR) in Crohn’s disase (CD) patients remains challenging. Compelling evidence supports therapeutic 
drug monitoring (TDM) to guide management in patients on infliximab, but data for other biologics are less robust. We aimed to asses if  empiric 
dose escalation led to improved clinical outcome in addition to TDM-guided optimization in CD patients with LOR to adalimumab (ADA).
Methods: Retrospective chart review of patients followed between 2014 and 2016 at McGill IBD Center with index TDM for LOR to ADA 
was performed. Primary outcomes were composite remission at 3, 6, and 12 months in those with empiric adjustments versus TDM-guided 
optimization.
Results: There were 104 patients (54.8% men) who were included in the study. Of this group, 81 patients (77.9%) had serum level (SL) ≥5µg/
ml at index TDM with a median value of 12µg/ml (IQR 6.1–16.5). There were 10 patients (9.6%) who had undetectable SL with high anti-ADA 
antibodies and 48 (46.2%) received empiric escalation. TDM led to change in treatment in 58 patients (55.8%). Among them, 28 (48.3%) had 
discontinued ADA, 12 (21.7%) had addition of immunomodulator or steroid, and 18 (31%) had ADA dose escalation. Empiric dose escalation 
before TDM-based optimization was not associated with improved outcomes at 3, 6, and 12 months, irrespective of SL levels. Clear SL cutoff  
associated with composite remission was not identified.
Conclusions: Our data do not support empiric dose adjustment beyond that based on the result of the TDM in patients with LOR to ADA. 
TDM limits unnecessary dose escalation and provides appropriate treatment strategy without compromising clinical outcomes.
Key Words:  loss of response, adalimumab, therapeutic drug monitoring
INTRODUCTION
Crohn’s disease (CD) is a chronic relapsing disorder that 
can lead to debilitating symptoms and morbid complications. 
No curative therapies are available and the current manage-
ment focuses on achieving disease remission with modulation 
of various inflammatory pathways.1, 2 Treatments utilizing 
monoclonal antibodies against TNF alpha (anti-TNFα) have 
been the most advanced therapeutic option available for CD 
in the last decade and became standard of care for the treat-
ment of patients with moderate-to-severe CD. Landmark 
trials confirmed their efficacy both in induction and mainte-
nance of the remission. Adalimumab (ADA), a completely 
human immunoglobulin G1 anti-TNFα monoclonal antibody, 
was approved in 2007 by the United States Food and Drug 
Administration to induce and maintain clinical remission in 
patients with moderate to severe active CD.3 Managing loss 
of response (LOR), however, remains a complex and frequent 
challenge in CD patients.
Advances in therapeutic drug monitoring (TDM) have 
led to significant improvements in the understanding of the 
relationship between anti-TNF-α drug concentrations, devel-
opment of antibodies, and disease activity. Emerging data 
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support the use of TDM to guide management decisions in cer-
tain scenarios in patients treated with infliximab (IFX), such as 
dose intensification, addition of immunomodulator, or switch-
ing out of class.4 Less data exists for ADA to support regular 
TDM. The current literature is still conflictive.5–9 A threshold 
of 4.9–5.9 µg/mL has been suggested for clinical remission and 
>7–10 µg/mL for mucosal healing.10, 11 Our retrospective study 
aimed to examine the clinical utility of TDM-guided ADA 
optimization for CD patients with LOR to ADA in a “real-life” 
setting at the McGill University Health Center (MUHC).
MATERIALS AND METHODS
Study Population and Design
We performed a retrospective cohort study including 
patients followed between June 2014 and November 2016 at the 
tertiary MUHC in Montreal, Canada. Eligible patients were 
identified through their index TDM test through the MUHC 
IBD Center and retrospective chart reviews were performed by 
the designated members of the research team (Sophie Restellini, 
Che-yung Chao ).
We included adult patients with established diagnosis of 
CD based on standard objective methodology (clinical, bio-
chemical, endoscopic, histological, and radiological criteria) and 
routine treatment with ADA at any time between January 2014 
and December 2016 (not including clinical trials). Patients with 
a minimum of one ADA TDM testing in the context of second-
ary LOR were included if  they had a minimum of 3 months fol-
low-up available following TDM testing. Secondary LOR was 
defined as those patients with Harvey-Bradshaw index (HBI) 
> 5 and/or biochemical evidence for active disease [C-reactive 
protein (CRP/fecal calprotectin (FCP)] and/or endoscopic find-
ings confirming active disease in patients who were in remission 
before; consistent current clinical practice. All patients who 
received a diagnosis of indeterminate colitis or ulcerative colitis 
and pediatric patients were excluded. The impact of perform-
ing TDM in those patients with secondary LOR was assessed. 
The remission rates and associated ADA level in patients who 
had dose escalation on a clinical basis, before the ADA level 
was available, were compared to those who had dose escalation 
based on the ADA level results.
For all eligible patients, the following demographic and 
clinical variables were collected if  available and analyzed: 
age, sex, date of diagnosis and duration of disease, extension 
and severity of disease defined by the Montreal classification, 
extraintestinal manifestations, prior surgery, prior treatment 
and reason for stopping, previous or current concomitant med-
ical therapy, dose of ADA and intervals of administration, 
duration of treatment, number of repeated TDM and date of 
collection, rationale for testing TDM, objective evidence of 
active disease, empiric change before TDM results such as dose 
escalation, deescalation, discontinuation, empiric addition of 
another drugs, ADA serum value, presence of anti-adalimumab 
antibodies (AAA), and posttest result change such as escal-
ation, deescalation, addition of another drug, or discontinu-
ation. Both the index TDM and subsequent repeat TDM results 
(if  available) were collected. Rates of complications, including 
hospitalization, surgery, adverse reaction, clostridium difficile 
infection, and corticosteroid use also were documented.
Additionally, serological variables including hemoglo-
bin concentration, white blood count, platelets level, albumin, 
CRP and FCP were also collected when available. Drug levels 
were measured on serum samples using a commercially avail-
able ELISA kit (Promonitor-ADL, Progenika Biopharma SA, 
Spain). Results were expressed as µg/mL. The reference cut 
points in our laboratory were as: < 5 ug/mL: subtherapeutic 
levels, between 5–20 ug/mL: therapeutic levels and > 20 ug/mL: 
supratherapeutic levels. Free ADA antibodies were measured in 
parallel to drug levels using the ELISA kit. AAA were detectable 
when their level was ≥10 AU//mL or undetectable if <10 AU/mL. 
As the drug level seem not to fluctuate over time for ADA, we 
have used the term serum level (SL) instead of trough level.
Clinical outcome was assessed by HBI, CRP, FCP, and 
endoscopic assessment by simple endoscopy score for CD 
(SES-CD) if  available at 3, 6, and 12 months following index 
TDM. Composite remission was defined as HBI<5, with 
CRP<5mg/L, FCP <250µg/g, and SES-CD score <3.
Our primary objective was to assess whether empiric 
dose escalation improves clinical outcome compared to TDM 
-guided optimization in CD patients with secondary LOR to 
ADA. Our secondary objective was to identify factors predic-
tive of composite remission for TDM-guided therapeutic opti-
mization and optimal ADA SL cutoffs. (Fig. 1)
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Statistical Analysis
Anonymized data were collected and stored in Excel in 
a password protected document. Statistical analyses were per-
formed using Statistical Package for the Social Sciences (SPSS 
20.0; SPSS INC., Chicago, Illinois). All continuous data were 
expressed as median ± inter-quartile range (IQR). Continuous 
variables were analyzed by a 2-tailed t test and the Mann–
Whitney U test. Logistic regression modeling was used to calcu-
late the odds ratios (ORs) and 95% confidence intervals (CIs). 
All P values were 2-tailed, and P values < 0.05 were considered 
statistically significant.
Ethical Considerations
The study was approved by the MUHC institutional 
review board and ethics committee (REB: 2017–2936).
RESULTS
Patient Characteristics
A total of 104 patients (54.8% men) ranging in age from 
18 years to 83 years (median 32, IQR 24–52) were included. Most 
patients (N = 70, 67.3%) were diagnosed between the age of 17 to 
40. The median duration of disease was 54 months (IQR 44–195) 
and 49 patients (47.1%) had a previous IBD-related surgery. There 
were 37 patients (35.6%) who were previously exposed to IFX and 
28 (26.9%) were on combotherapy with azathioprine/6-mercapto-
purine at the time of TDM measurement. The patient demograph-
ics at baseline for the entire cohort are summarized in Table 1. 
Additional information for those included in the primary end 
point analysis at 3 months are presented in supplementary Table 1.
TDM Results
The majority of patients (N = 80, 76.9%) had serum lev-
els (SL) ≥5µg/ml at the index TDM. Median ADA SL was 12µg/
ml with IQR 6.1–16.5. Among them, 9.6% (N = 10) had unde-
tectable drug level with positive AAA (all of whom had high 
antibody levels of ≥10AU/ml).
TDM-guided Therapeutic Adjustments
TDM result led to immediate change in treatment in 
55.8% of all patients out of which, 48.3% had discontinued 
ADA, 21.7% had an addition of an immunomodulator or ster-
oids, and 31% had ADA dose escalation (Fig. 2). The majority 
(76.5%) of the TDM-guided changes occurred within 1 month 
(Mean 1.7 SD 0.9) of the index testing. Fifty percent of those 
discontinued ADA changed to another anti-TNF agent and 
50% changed to ustekinumab.
Clinical Outcomes for Empiric Versus TDM-
guided Adjustments
In those with LOR to ADA, empiric dose escalation was 
not associated with improved composite remission at 3 months 
when compared to the TDM-guided therapy group (16% vs 
42.31%, P = 0.619). Multivariate logistic regression analysis was 
used to adjust for baseline characteristic differences between 2 
groups. Similarly, the 6- and 12-months composite remission 
did not differ significantly (30.77% vs 45.5%, P = 0.328, 27.3% 
vs 39.39%, P = 0.978, respectively) (Fig. 3). Only 18 (17.3%) 
of patients had endoscopic assessment data available, and 
there was no difference between the 2 groups in terms of endo-
scopic remission rates (33.3% vs 33.3%). There was no signifi-
cant difference in median SL between those who had empiric 
dose escalation before TDM results versus others (P = 0.194). 
Similar outcome was also observed for the end points of 
mucosal healing, IBD-related surgery, and hospitalization 
rates. In those with index SL ≥ 5 ug/mL empiric dose escalation 
was associated with lower composite remission at 3  months 
compared to those with TDM-guided adjustment (12.5% vs 
47.1%, P = 0.034). No difference was found at 6 and 12 months 
between these two cohorts (29.4% vs 54.2%, P = 0.120, 37.5% 
vs 39.1%, P = 0.919). Finally, for patients on standard ADA 
dosing of 40mg every other week, there was still no differences 
between the empiric escalation and the TDM group at 3 (28.6% 
vs 47.1%, P = 0.413), 6 (60% vs 55%, P = 0.844), and 12 (33.3% 
vs 47.4%, P = 0.656) months.
Empiric Dose Escalation
ADA dose was empirically escalated before TDM results 
became available in 48 patients (46.2%). These patients were 
more likely to have ileal disease (P < 0.001), stricturing pheno-
type (P = 0.005), concurrent steroid use (P = 0.001), longer ADA 
treatment duration (P < 0.001), higher HBI (P = 0.015), higher 
FCP (P = 0.003), lower albumin (P = 0.041), and less likely to be 
on standard ADA dose (P = 0.001). Sixteen of these patients dis-
continued ADA following TDM results and the majority of them 
(87.5%) due to adequate SL. In addition, 58 patients (55.8%) had 
no empiric changes and 37.5% of these patients were already on 
a higher than standard dosing regimen of 40mg every 2 weeks.
Clinical Outcomes of Serum Levels ≥5 versus 
<5µg/ml
Composite remission rate at 3 and 6 months were not dif-
ferent in patients with therapeutic SL (≥5µg/ml) compared to 
patients with SL (<5µg/ml) (31.3% vs 29.4%, P = 0.900, 33.3% 
vs 57.1%, P = 0.510, respectively). Furthermore, receiver oper-
ating curve analysis failed to identify a particular SL cutoff that 
statistically differentiated between those achieving composite 
remission at 3 and 6 months, with others not in remission (area 
under curve: 0.43).
Predictors of Composite Remission in Patients 
with LOR to ADA following TDM-guided 
Therapeutic Optimization
A 3-months composite remission was more likely to 
occur in patients with shorter disease duration (P  =  0.038), 
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platelets (P = 0.035), and higher albumin (P = 0.001) (Table 2). 
Additionally, those achieving composite remission at 3 months 
had higher baseline FCP .
A 12-months composite remission was more likely to 
occur in patients naive to IFX (P = 0.025), older age at diagno-
sis (P < 0.05), higher baseline hemoglobin (P = 0.001), higher 
TABLE 1: Patient Baseline Characteristics
Empiric TDM Pvalue
No. overall (104) 48 56
Males, no. (%) 26 (54.2% %) 32 (7.1% %) 0.768
Age at TDM, median (range) 36 (18–75) 30 (17.83) 0.075
Extraintestinal manifestations (n, %) 23 (47.9%) 12 (21.4%) 0.004
IBD-related surgery (no., %) 21 (45.7%) 26 (46.4%) 0.943
Disease duration (months, IQR) 120 (59–228) 78 (36–171) 0.095
Age at diagnosis
 A1 (<16) 14 (29.2%) 16 (28.6%) 0.947
 A2 (17–40) 33 (68.8%) 37 (66.1%) 0.771
 A3 (>40) 1 (2.1 %) 3 (5.4 %) 0.387
Disease location: CD
 L1-terminal ileum 14 (29.2%) 12 (21.4%) 0.362
 L2-colon 33 (68.8%) 16 (28.6%) <0.0001
 L3-ileocolonic 1 (2.1%) 27 (48.2%) <0.0001
 L4: upper GI tract 0 1 (1.8%) 0.353
Disease behavior: CD
 B1- Inflammatory 18 (37.5%) 33 (68.8%) 0.102
 B2-Stricturing 26 (54.2%) 30 (53.6%) 0.0003
 B3-Penetrating 4 (8.3%) 11 (19.6%) 0.0154
Perianal disease, n (%) 15 (31.3%) 15 (26.8%) 0.615
HBI at TDM 6 (4–8) 5 (1–7) 0.015
Endoscopic activity (SES-CD score, median, IQR) 9 (5–12) 5 (3–8) 0.095
Biochemical assessment (median, IQR)
 Hemoglobin (g/l) 130 (120–142) 130 (133–142) 0.229
 White blood cell (g/l) 6.8 (5.6—8.5) 7.6 (6.1–9.7) 0.308
 Platelet (g/l) 278 (225–337) 266 (194–360) 0.619
 Albumin (g/l) 39 (36–42) 41 (38–43) 0.040
 CRP (mg/l) 7.7 (2.1–21.9) 3.2 (1–7.8) 0.112
 FCP (ug/g) 266 (121–687) 509 (126--1801) 0.003
Treatment
 Prior IFX treatment  21 (43.8%)  16 (26.8 %) 0.071
 Oral corticosteroids 13 (27.1%) 2 (3.6%) 0.0007
 Immunomodulators:
  Azathioprine/mercaptopurine 16 (33.30%) 12 (21.4%) 0.175
  Methotrexate 2 (4.2%) 2 (3.6%) 0.875
 Duration of ADA in months (median, IQR) 22 (6–36) 10 (4–24) <0.0001
 Dosage:
  40 mg EOW 12 (25%) 35 (62.5%) 0.0001
  40 mg Weekly 32 (66.7%) 20 (35.7%) 0.0017
  80 mg EOW 1 (2.1%) 0 0.278
  80 mg Weekly 3 (6.3%) 1 (1.8%) 0.238
No., Number; TDM, therapeutic drug monitoring; IBD, Inflammatory bowel disease; IQR, Interquartile range; GI, gastrointestinal; HBI, Harvey Bradshaw Index; SES-CD: 
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baseline albumin (P = 0.001), lower baseline CRP (P = 0.035), 
and lower baseline FCP (P = 0.043) (Table 3).
None of the outcomes was associated with past IFX 
exposure, ADA serum level and antibody level.
Patients with Positive Antibodies Against ADA 
Out of the 10 patients with high AAA, 1 was on combin-
ation therapy with an immunomodulator. All of them discon-
tinued ADA in light of the TDM results. Four of these patients 
were IFX naive patients and were switched to IFX. The oth-
ers were IFX experienced patients and they were switched to 
ustekinumab (N = 5) and golimumab (N = 1).
DISCUSSION
LOR to ADA remains a major problem for the man-
agement of CD with an estimated incidence rate of 30%. In 
primary anti-TNF responders, around 36% will require ADA 
dose intensification.12 Previous studies have attempted to dem-
onstrate the clinical utility of an algorithmic approach to ther-
apeutic optimization based on TDM results.13, 14 Conversely, 
others have also shown that empiric ADA dose escalation is 
effective in recapturing disease control after secondary LOR.15 
Currently there is no randomized controlled study examining 
whether empiric dose adjustments lead to improved outcomes 
as compared to those with TDM-guided changes for ADA.
FIGURE 2. TDM- guided treatment changes postindex test results between empiric dose escalation versus TDM-based adjustment group.
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This present study is the largest retrospective study to date 
which compared the clinical utility of empiric versus TDM-
based strategy. In patients with secondary LOR to ADA, empiric 
dose escalation before TDM results were not associated with bet-
ter outcomes at 3 months, irrespective of the SL. Multivariable 
analysis was utilized to adjust for potential confounding differ-
ences in baseline disease activity and characteristics. Similarly, 
it also did not lead to improved outcomes at 6 and 12 months. 
Therefore, treatment optimization should be guided by TDM 
results. Even though the physicians were not blinded to the TDM 
results, this actually reflects the real-world clinical practice where 
clinicians could empirically dose escalate and/or use TDM- 
guided approach in their management. Furthermore, despite 
intention of early action with TDM results, there will always be a 
TABLE 2: Predictors of Composite Remission in Patients with TDM-Based Dose Adjustment at 3 Months
No Composite Remission Composite Remission Pvalue
Males (%) 41.70 40 0.911
Age at TDM, median (range) 39 (17–74) 30 (19–62) 0.046
Extraintestinal manifestations (%) 36.10 20 0.264
IBD-related surgery (%) 53.8 26.7 0.080
Disease duration (median months, IQR) 142 (36–223) 66 (23–90) 0.038
Age at diagnosis (%):
 A1 (<16) 22.2 20.0 0.863
 A2 (17–40) 72.2 73.3 0.937
 A3 (>40) 5.6 6.7 0.881
Disease location (%):
 L1-terminal ileum 22.2 26.7 0.733
 L2-colon 22.2 40.0 0.199
 L3-ileocolonic 52.8 33.3 0.208
 L4: upper GI tract 2.8 0 0.517
Disease behavior (%):
 B1- Inflammatory 41.7 60.0 0.238
 B2-Stricturing 36.1 26.7 0.521
 B3-Penetrating 22.2 13.3 0.470
Perianal disease (%) 33.3 26.7 0.567
HBI at TDM (median, IQR) 6(5–8) 4(1–7) 0.076
Biochemical assessment (median, IQR):
 Hemoglobin (g/l) 9 (116–132) 7 (127–143) 0.241
 White blood cell (g/l) 7.3 (5.7–8.6) 8.7 (6.2–9.8) 0.125
 Platelet (g/l) 338 (274–382) 261 (195–350) 0.025
 Albumin (g/l) 37 (33–41) 41 (40–43) 0.030
 CRP (mg/l) 19.4 (1.5–29.8) 11.8 (2.5–9.2) 0.340
 FCP (ug/g) 600 (119–798) 1143 (717–1801) 0.018
Treatment (%):
 Prior IFX treatment 41.7 20.0 0.144
 Oral corticosteroids 16.7 6.7 0.350
 Immunomodulators:
  Azathioprine/mercaptopurine 19.4 26.7 0.567
  Methotrexate 2.8 0 0.517
 Duration of ADA in months (median, IQR) 22 (5–33) 10 (4–19) 0.063
 Dosage (%):
  40 mg EOW 38.9 66.7 0.073
  40 mg Weekly 50 33.3 0.280
  80 mg EOW 0 0 -
  80 mg Weekly 11,1 0 0.183
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delay due to results turnover time and the logistics involved with 
therapeutic changes. This study confirmed that early empiric 
changes did not lead to meaningful clinical improvements.
Moreover, the systematic review by Martelli and colleagues 
has demonstrated that TDM treatment strategy leads to major 
cost savings in IBD and rheumatoid arthritis without negative 
impact on efficacy. Indeed, more than half of the patients in 
this LOR to ADA cohort had treatment adjustments based on 
TDM without inferior clinical outcomes subsequently. Finally, 
the development of point of care anti-TNF SL and AAA testing 
may further improve cost effectiveness of this strategy by short-
ening the time delay with the standard results turnover interval.16
TABLE 3: Predictors of Composite Remission in Patients with TDM-Based Dose Adjustment at 12 Months
No Composite Remission Composite Remission Pvalue
Males (%) 58.3 36.8 0.133
Age at TDM, median (range) 38 (17–75) 33 (18–62) 0.231
Extraintestinal manifestations (%) 33.3 36.8 0.797
IBD-related surgery (%) 55.6 47.4 0.566
Disease duration (months, IQR) 156 (46–208) 102 (30–114) 0.192
Age at diagnosis (%):
 A1 (<16) 19.4 31.6 0.315
 A2 (17–40) 84.6 57.9 0.030
 A3 (>40) 0 10.5 0.049
Disease location (%):
 L1-terminal ileum 19.4 26.3 0.559
 L2-colon 16.7 26.3 0.402
 L3-ileocolonic 63.9 47.4 0.242
 L4: upper GI tract 0 0 -
Disease behavior (%):
 B1- Inflammatory 38.9 47.4 0.547
 B2-Stricturing 38.9 31.6 0.596
 B3-Penetrating 22.2 21.1 0.926
Perianal disease (%) 30.6 26.3 0.741
HBI at TDM (median, IQR) 6 (4–7) 4 (0–6) 0.052
Biochemical assessment (median, IQR):
 Hemoglobin (g/l) 123 (114–136) 136 (132–140) 0.009
 White blood cell (g/l) 7.9 (5.1–11) 7.5 (5.8–9.6) 0.848
 Platelet (g/l) 326 (259–379) 278 (198–360) 0.122
 Albumin (g/l) 37 (33–41) 42 (40–43) 0.001
 CRP (mg/l) 19.4 (3.2–23.5) 7 (0.6–3.6) 0.035
 FCP (ug/g) 946 (316–1656) 523 (104–749) 0.043
 Index ADA SL 12.4 (3.5–14.9) 10.6 (6.4–13.5) 0.533
Treatment (%):
 Prior IFX treatment 52.8 21.1 0.025
 Oral corticosteroids 13.9 5.3 0.336
 Immunomodulators: 30.6 42.1 0.398
  Azathioprine/mercaptopurine 2.8 5.3 0.642
  Methotrexate
 Duration of ADA in months (median, IQR) 21 (4–32) 16 (6–24) 0.374
 Dosage (%):
  40 mg EOW 33.3 52.6 0.169
  40 mg Weekly 55.6 47.4 0.556
  80 mg EOW 0 0 -
  80 mg Weekly 11,1 0 0.135
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Serum ADA level was not associated with treatment out-
come in this cohort. Some patients in this cohort (37.5%) were 
already on a higher ADA dose and 76.9% had serum ≥5  µg/
ml at index TDM that may have limited the power to detect 
differences and could limit the generalizability of the study 
results to all ADA patients with LOR since an attempt to opti-
mize the dosage of ADA had already been made. However, 
in the sub-analysis for those on standard ADA 40mg every 
other week, there were still no differences in clinical outcomes 
between the empiric escalation and TDM group. This adds to 
the current debate on the optimal cutoff  of SL and AAA levels 
in relation to clinical outcomes. In a trial of 130 patients receiv-
ing maintenance therapy with ADA who had available serum 
samples, no relationship was reported between outcomes at 4 
weeks and SL of ADA. SL were significantly lower in those who 
discontinued ADA use (P = 0.012).17 Another study examined 
the impact of SL in a subgroup of 48 patients receiving ADA, 
of whom 24 were in both clinical and endoscopic remission. 
Twenty-one of 24 patients meeting these criteria had through 
levels >2 μg/ml. However, in this study, 17 of 24 who did not 
reach deep remission also had ADA levels above this cutoff. 
Conversely, a recent meta-analysis revealed that patients with 
ADA SL over >5.9 µg/mL were more likely to achieve remission 
(OR = 2.6 (95% CI: 1.79–3.77, P < 0.0001)).18 Higher ADA SL 
were also likely to be associated with sustained clinical response 
(P = 0.01).17 Similarly, SL of ADA were also higher in patients 
who achieved mucosal healing (6.5  μg/mL) than in patients 
without (4.2 μg/mL; P < 0.005).
Several predictors of clinical response following TDM-
guided optimization were identified. These were predominantly 
factors associated with lower index clinical disease activity or 
biochemical markers such as index hemoglobin, albumin, CRP, 
and platelets indirectly reflecting lower inflammatory burden 
and, therefore, higher likelihood of responding to therapy 
adjustments. Potential mechanisms underlying this intuitive 
observation may be related to higher anti-TNF drug clearance 
through the reticuloendothelial system and gut loss in the set-
ting of higher inflammatory activity and the need of higher 
drug levels to overcome the degree of inflammation.19
The main limitations to this study are inherent to the 
retrospective nature of  the study design that included selec-
tion bias, potential missing data, and inability to control for 
potential confounding factors. For example, it was difficult 
to adjust for medication compliance, access to recommended 
dose optimization due to financial or logistic issues, time delay 
differences in treatment adjustment following TDM, and mul-
tiple adjustments and their correlation with subsequent TDM 
results. Furthermore, only 17% of the cohort had mucosal 
healing assessment within 12  months and less than 3% had 
IBDrelated surgery and hospitalization, thus, this may have 
limited the power to detect significant differences in these 
objective endpoints. It is the standard practice in this institu-
tion that patients with secondary LOR will be assessed with 
TDM irrespective of  empiric dosing changes thus limiting the 
potential selection bias of  including only patients with TDM 
results.
CONCLUSIONS
In summary, in CD patients with secondary LOR to ADA, 
empiric dose escalation before TDM-guided optimization did not 
lead to improved clinical outcome and therefore is unnecessary.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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